Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Non-Cancer Life Stressors Contribute to Impaired Quality of Life in Ovarian Cancer Patients

Highlights Number and severity of life stressors were unrelated to participants’ quality of life (QOL) before surgery. Greater number of life stressors at one-year post surgery was related to poorer … Continue reading

October 16, 2013

Marital Status and Survival in Patients With Cancer

This SEER database study demonstrated that unmarried patients were at a greater risk of late-stage diagnosis, undertreatment, and cancer-related death. The effects were more pronounced in males than females.  Ayal … Continue reading

October 16, 2013

The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

“Recent studies suggest that carboplatin with pegylated liposomal doxorubicin (C+PLD) is as efficacious as carboplatin with paclitaxel (C+P) and possibly is more tolerable for ovarian cancer therapy.”  Jean-Marie Gibson, Saeed … Continue reading

October 16, 2013

Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer

“Trebananib added to paclitaxel significantly improved progression-free survival (PFS) in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.”  Bonnie Gillis http://www.onclive.com/conference-coverage/ecco-esmo-2013/Trebananib-Shows-Promise-in-Recurrent-Platinum-Sensitive-Ovarian-Cancer?auto_reg_id=&utm_source=Informz&utm_medium=OncLive&utm_campaign=ESMO%20Conference%20Day4%2010-03-13 Trebananib … Continue reading

October 16, 2013

Pre-operative Imaging with CA125 is a Poor Predictor for Granulosa Cell Tumors

Granulosa cell tumors are almost exclusively complex and are most frequently greater than 10 cm. There was a near equal distribution of granulosa cell tumors with a CA125 greater than … Continue reading

October 16, 2013

Ovarian Cancer: A Brief Historical Overview of Intraperitoneal Trials

“In this article, we highlight the key trials and recent directions in IP therapy of ovarian cancer and briefly discuss another approach to the delivery of IP chemotherapy, known as … Continue reading

October 16, 2013

Misperceptions of Ovarian Cancer Risk in Women at Increased Risk for Hereditary Ovarian Cancer

“A large number of women at increased risk for ovarian cancer overestimate their risk. This is of concern…”  Meiser B, Price MA, Butow PN, Rahman B, Tucker K, Cheah B, … Continue reading

October 16, 2013

Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin

“This experience suggests that IP cisplatin leads to favorable long term outcomes in advanced ovarian cancer in women with defective homologous recombination (i.e., with deleterious BRCA mutations). Whether such cisplatin … Continue reading

October 16, 2013

Versatile microRNAs Choke Off Cancer Blood Supply, Suppress Metastasis

A new study released today by MD Anderson Cancer Center in Texas shows that a family of microRNAs (miR-200) blocks cancer progression by cutting off the tumor’s ability to build … Continue reading

October 16, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada